Roivant Sciences' stock advanced during Wednesday's trading, reflecting a positive market response to the latest developments in its subsidiary Immunovant, Inc.'s core pipeline asset IMVT-1402 and the company's upcoming earnings report.

Investor attention is centered on IMVT-1402, a next-generation FcRn inhibitor developed by Immunovant, Inc. for treating autoimmune diseases such as myasthenia gravis. This focus follows the discontinuation of development for the first-generation product, batoclimab, in the thyroid eye disease indication after it failed to meet primary endpoints in two Phase 3 trials. This outcome has led the company to fully pivot its efforts toward advancing IMVT-1402.

Recent clinical progress and corporate activity have been positive. The company recently reported encouraging data for IMVT-1402. In a Phase 2 proof-of-concept study for Graves' disease, the drug met both primary and secondary endpoints, demonstrating disease-modifying potential. Based on these results, registration trial data for this indication is anticipated in 2027. Concurrently, the market is closely watching for further details on the development plans for IMVT-1402, which management is expected to elaborate on during the release of the fiscal year 2026 fourth quarter and full-year financial results scheduled for May 20.

Several analytical institutions are optimistic about IMVT-1402's prospects, suggesting its success could drive peak sales exceeding $10 billion for Roivant. Some analysis indicates that Roivant's current stock price may be undervalued by approximately 20%, with a potential fair value estimated around $35.67 per share. Roivant's current market capitalization stands at approximately $22 billion.